- Pharmaceutical companies
- Europe
- Germany
- Daiichi Sankyo Co., Ltd.
Daiichi Sankyo Co., Ltd. in Germany
E-mail: service@daiichi-sankyo.eu
Web: https://www.daiichi-sankyo.eu/
Address:
-
Daiichi Sankyo Europe GmbH
Zielstattstr. 48 81379 Munich
Phone: +498978080
Other Daiichi Sankyo Co., Ltd.'s locations around the world
Clinical Trials sponsored by Daiichi Sankyo Co., Ltd.
-
Daiichi Sankyo Co., Ltd.ReclutamentoTumore solido | Tumore solido metastatico | Cancro avanzatoGiappone, Stati Uniti, Canada
-
Daiichi Sankyo Co., Ltd.Attivo, non reclutanteTumore a cellule giganti tenosinovialeTaiwan, Cina
-
Daiichi Sankyo Co., Ltd.Daiichi SankyoAttivo, non reclutante
-
Daiichi Sankyo Co., Ltd.Daiichi SankyoAttivo, non reclutanteMelanomaCorea, Repubblica di, Cina
-
Daiichi SankyoDaiichi Sankyo Co., Ltd.Attivo, non reclutanteCancro polmonare non a piccole cellule metastatico | Carcinoma polmonare non a piccole cellule con mutazione nel recettore del fattore di crescita epidermicoStati Uniti, Spagna, Corea, Repubblica di, Francia, Regno Unito, Taiwan, Australia, Giappone, Cina, Olanda, Italia, Germania, Austria, Belgio, Bulgaria, Singapore
-
Daiichi Sankyo Co., Ltd.Attivo, non reclutanteLeucemia/Linfoma a cellule T dell'adultoGiappone
-
Daiichi SankyoDaiichi Sankyo Korea Co., Ltd.Attivo, non reclutante
-
Daiichi SankyoAstraZeneca; Daiichi Sankyo Co., Ltd.Attivo, non reclutanteCancro al senoCina, Stati Uniti, Spagna, Ungheria, Israele, Corea, Repubblica di, Taiwan, Belgio, Austria, Federazione Russa, Svizzera, Portogallo, Francia, Canada, Italia, Regno Unito, Grecia, Giappone, Germania, Svezia
-
Daiichi SankyoAstraZeneca; Daiichi Sankyo Co., Ltd.Attivo, non reclutanteCancro al senoStati Uniti, Spagna, Israele, Italia, Corea, Repubblica di, Belgio, Australia, Cechia, Giappone, Brasile, Francia, Regno Unito, Tacchino, Grecia, Germania
-
Daiichi Sankyo Co., Ltd.CompletatoTumore gastricoCorea, Repubblica di, Hong Kong, Taiwan, Cina
About Daiichi Sankyo Co., Ltd.
Daiichi Sankyo Company, Limited (Japanese: 第一三共株式会社, Hepburn: Daiichi Sankyō Kabushiki-gaisha) is a global pharmaceutical company and the second-largest pharmaceutical company in Japan. It achieved JPY 981.8 billion in revenue in 2019. The company owns the American biotechnology company Plexxikon, American pharmaceutical company American Regent, German biotechnology company U3 Pharma, and recently sold Ranbaxy Laboratories in India. Daiichi Sankyo Co., Ltd. is the producer of Benicar (Olmesartan), an angiotensin II receptor antagonist and top selling drug in the U.S. Global sales of Olmesartan in 2013 were 300.2 billion yen. Daiichi Sankyo, Inc. (DSI) began operating in the U.S. in 2006. It is the U.S. subsidiary of Daiichi Sankyo Company, Limited, and a member of the Daiichi Sankyo Group. The organization, which includes U.S. commercial operations and global clinical development (Daiichi Sankyo Pharma Development), is headquartered in Basking Ridge, New Jersey. Daiichi Sankyo Europe, GmbH (DSE), the European subsidiary, is headquartered in Munich, Germany. The organization is responsible for development and manufacturing for 12 European countries. Daiichi Sankyo Company, Limited is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).